Introduction Human civilisation faces such global catastrophic risks as a: nuclear war, bioengineered pandemic, major solar storm, and volcanic winter. For some of these catastrophes, island nations may have relative survival potential but any collapse in international trade could also end critical imported goods such as pharmaceuticals. We aimed to explore the latter using the case study country of Aotearoa New Zealand (NZ).

Methods We identified the 10 most extensively prescribed pharmaceuticals in NZ that are used for acute treatment (by annual prescription numbers). Based on modern synthesis pathways for these pharmaceuticals in the literature, we identified ingredients and then determined if these ingredients were currently produced in NZ.

Results The results suggest that none of these 10 pharmaceuticals could be produced in NZ in a trade-ending catastrophe: paracetamol, omeprazole, amoxicillin, ibuprofen, aspirin, metoprolol succinate, salbutamol, prednisone, cetirizine hydrochloride, and amlodipine. This is primarily because NZ does not refine petrochemicals. For seven of these 10 pharmaceuticals the relevant catalysts or other specific chemical ingredients are also not mined or otherwise produced in NZ. There may, however, be some scope for the post-catastrophe scavenging of minerals for producing some catalysts.

Conclusions This preliminary analysis suggests that none of the 10 most extensively prescribed pharmaceuticals used for acute treatments could be manufactured in this case study country after a trade-ending global catastrophe. To address this and other domains lacking in resiliency (eg, liquid fuel supply), a research programme for building shared resiliency with other neighbouring nations (eg, Australia) could be considered.

The authors have declared no competing interest.

The author(s) received no specific funding for this work.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study did not require ethical review as it was about the potential for pharmaceutical manufacturing in post-catastrophe situations and did not involve any human participants.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are within the manuscript and its Supporting Information files.